📊 BFRIW Key Takeaways
Is Biofrontera Inc. (BFRIW) a Good Investment?
Biofrontera demonstrates deteriorating fundamental health despite modest revenue growth. Severe cash burn of $13.4M annually combined with negative profitability across all metrics suggests the company is consuming capital at an unsustainable rate. With only $6.4M in cash and negative operating cash flow, the company faces significant liquidity pressure without a clear path to profitability.
Biofrontera shows some top-line momentum and materially improved net losses, but the core business remains structurally unprofitable with deeply negative operating margins and cash flow. The balance sheet is helped by no meaningful debt and acceptable near-term liquidity, yet the current cash position looks thin relative to ongoing operating cash burn, which weakens the quality of the growth story.
Why Buy Biofrontera Inc. Stock? BFRIW Key Strengths
- Revenue growth of 11.7% year-over-year shows top-line expansion
- Positive cash position of $6.4M provides some operational runway
- Low leverage with 0.00x debt-to-equity ratio reduces financial stress
- Revenue grew 11.7% year over year, indicating continued commercial traction
- Net loss and diluted EPS improved meaningfully versus the prior year
- Balance sheet leverage is low, with 0.00x debt-to-equity and a 1.52x current ratio
BFRIW Stock Risks: Biofrontera Inc. Investment Risks
- Severe cash burn of $13.4M annually with only 5.7 months of runway at current burn rate
- Consistently negative profitability with -25.3% net margin and -27.2% operating margin
- Operating cash flow of -$13.4M indicates core business cannot fund operations
- Negative ROE of -100.5% and ROA of -36.9% demonstrate capital destruction
- Free cash flow margin of -32.0% indicates value destruction on every dollar of revenue
- Operating margin of -27.2% and net margin of -25.3% show the business is still far from sustainable profitability
- Operating cash flow and free cash flow were both -$13.36M, indicating heavy ongoing cash burn
- Cash of $6.39M appears limited relative to annual cash outflows, raising funding and dilution risk if trends do not improve
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF
- Monthly cash burn rate and cash runway remaining
- Revenue growth sustainability and gross margin if disclosed
- Operating leverage improvements and timeline to EBITDA profitability
- Operating cash flow burn relative to cash balance
- Operating margin improvement alongside revenue growth
Biofrontera Inc. (BFRIW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Biofrontera Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BFRIW Profit Margin, ROE & Profitability Analysis
BFRIW vs Healthcare Sector: How Biofrontera Inc. Compares
How Biofrontera Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biofrontera Inc. Stock Overvalued? BFRIW Valuation Analysis 2026
Based on fundamental analysis, Biofrontera Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biofrontera Inc. Balance Sheet: BFRIW Debt, Cash & Liquidity
BFRIW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biofrontera Inc.'s revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.22 indicates the company is currently unprofitable.
BFRIW Revenue Growth, EPS Growth & YoY Performance
BFRIW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $7.0M | -$5.7M | $-0.62 |
| Q2 2025 | $7.8M | -$257.0K | $-0.05 |
| Q1 2025 | $7.9M | -$4.2M | $-0.47 |
| Q3 2024 | $8.9M | -$5.7M | $-0.98 |
| Q2 2024 | $5.8M | -$257.0K | $-0.05 |
| Q1 2024 | $7.9M | -$7.5M | $-2.88 |
| Q3 2023 | $4.3M | $2.1M | $2.19 |
| Q2 2023 | $4.5M | -$850.0K | $-0.90 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biofrontera Inc. Dividends, Buybacks & Capital Allocation
BFRIW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biofrontera Inc. (CIK: 0001858685)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BFRIW
What is the AI rating for BFRIW?
Biofrontera Inc. (BFRIW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BFRIW's key strengths?
Claude: Revenue growth of 11.7% year-over-year shows top-line expansion. Positive cash position of $6.4M provides some operational runway. ChatGPT: Revenue grew 11.7% year over year, indicating continued commercial traction. Net loss and diluted EPS improved meaningfully versus the prior year.
What are the risks of investing in BFRIW?
Claude: Severe cash burn of $13.4M annually with only 5.7 months of runway at current burn rate. Consistently negative profitability with -25.3% net margin and -27.2% operating margin. ChatGPT: Operating margin of -27.2% and net margin of -25.3% show the business is still far from sustainable profitability. Operating cash flow and free cash flow were both -$13.36M, indicating heavy ongoing cash burn.
What is BFRIW's revenue and growth?
Biofrontera Inc. reported revenue of $41.7M.
Does BFRIW pay dividends?
Biofrontera Inc. does not currently pay dividends.
Where can I find BFRIW SEC filings?
Official SEC filings for Biofrontera Inc. (CIK: 0001858685) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BFRIW's EPS?
Biofrontera Inc. has a diluted EPS of $-1.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BFRIW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biofrontera Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BFRIW stock overvalued or undervalued?
Valuation metrics for BFRIW: ROE of -100.5% (sector avg: 15%), net margin of -25.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BFRIW stock in 2026?
Our dual AI analysis gives Biofrontera Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BFRIW's free cash flow?
Biofrontera Inc.'s operating cash flow is $-13.4M, with capital expenditures of $2.0K. FCF margin is -32.0%.
How does BFRIW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -25.3% (avg: 12%), ROE -100.5% (avg: 15%), current ratio 1.52 (avg: 2).